Chapter review

Fitzgerald PMHNP board review. ch02. Select Special Topics in Psychiatric-Mental Health Practice. This is drive 17 of 18. When I say Pause. Answer. wait, then I will give the answer. New section. Fitzgerald Sample Question Scenarios. Topic. Sample: Identifying principle of Beneficence. Bottom Line. Bottom line. **Beneficence** is the foundational bioethical principle defined as the healthcare provider's obligation to act in the best interest of the patient, promote health and well-being, and actively help individuals in need. In PMHNP practice, **beneficence** underpins clinical decision-making, patient advocacy, health promotion, and the delivery of evidence-based treatments while minimizing potential risks. Key Concepts on Beneficence and Bioethical Principles. * Beneficence: The moral and professional obligation to do good, promote patient welfare, and provide interventions that benefit the client. * Nonmaleficence: The duty to do no harm, whether intentionally or unintentionally, and to minimize harm when risks are unavoidable (viewed as a corollary to **beneficence**). * Autonomy: The right of a competent individual to self-determination, independence, and making voluntary decisions regarding their healthcare. * Justice: The obligation to treat all individuals fairly, equitably, and without prejudice, regardless of socioeconomic status, race, gender, or diagnosis. * Veracity: The duty to tell the truth, provide full disclosure, and refrain from misrepresentation or deception. * Fidelity: The commitment to be faithful, keep promises, maintain confidentiality, and honor professional duties to the patient. Safety Alert. Safety alert. Never allow paternalism to override patient autonomy under the guise of **beneficence** when a patient possesses decision-making capacity. Paternalism occurs when a clinician unilaterally makes healthcare decisions for a competent patient believing it is for their own good. Overriding a competent patient's refusal of treatment violates autonomy unless the patient lacks capacity, poses an imminent danger to self or others, or is subject to a formal legal court order. Board Trap. Board trap. Do not confuse **beneficence** with **nonmaleficence** or **paternalism**. **Beneficence** means actively taking positive steps to help the patient (doing good), whereas **nonmaleficence** means refraining from actions that cause harm (doing no harm). On board exams, if a question asks which principle is demonstrated when a provider actively helps a patient access needed care or prescribes an effective evidence-based therapy, the answer is **beneficence**. First-Line. First-line. Your **first-line** ethical approach in psychiatric nursing is integrating **beneficence** with respect for patient autonomy through shared decision-making, providing comprehensive education on treatment risks and benefits, and advocating for the least restrictive therapeutic environment. Compare and Distinguish. Beneficence vs. Nonmaleficence. * Think Beneficence when: The provider takes active steps to promote health, relieve suffering, and do good for the patient. * Think Nonmaleficence when: The provider avoids causing harm, prevents injury, or takes steps to minimize unavoidable side effects or treatment risks. * Priority difference: Beneficence is a positive duty to act for patient benefit, whereas nonmaleficence is a negative duty to refrain from harmful actions. * What boards are testing: Differentiating active benefit promotion from harm avoidance. Autonomy vs. Paternalism. * Think Autonomy when: The provider respects and supports the competent patient's right to accept or refuse medical treatment. * Think Paternalism when: The provider overrides a patient's preferences under the assumption that the clinician knows what is best for the patient. * Priority difference: Autonomy upholds self-determination, whereas paternalism restricts choice for perceived well-being. * What boards are testing: Recognizing when clinician actions cross the boundary into unauthorized paternalism. Printed Fitzgerald Sample Questions. Question 1 (Fitzgerald Sample Item). Which of the following best describes the ethical principle of beneficence? - A. The right of the competent person to choose a personal plan of life and action. - B. The obligation of the healthcare provider to help people in need. - C. The duty of the healthcare provider to do no harm. - D. The responsibility of the healthcare provider to treat all in a fair and equitable manner. Pause. Answer. B. Why it is correct: Beneficence is defined as the healthcare provider's obligation to act for the benefit of others and help people in need. Why each distractor fails: - A. Choice A defines the principle of autonomy, which protects self-determination and personal choice. - C. Choice C defines nonmaleficence, which mandates doing no harm and minimizing risk. - D. Choice D defines justice, which requires fair and equitable treatment for all individuals. Test-taking pearl: Beneficence means actively helping patients in need and promoting their well-being. Concept tested: Defining the core bioethical principle of beneficence. Live Board Practice Items. Question 2. A PMHNP meets with a 30-year-old patient who has stable major depressive disorder. The patient expresses concern about potential side effects of a newly suggested medication. The PMHNP takes time to explain the expected benefits, potential risks, and alternative options, encouraging the patient to participate in choosing the final treatment plan. Which ethical principles are primarily demonstrated by the PMHNP's actions? - A. Beneficence and respect for autonomy - B. Nonmaleficence and paternalism - C. Justice and fidelity - D. Veracity and utilitarianism Pause. Answer. A. Why it is correct: Explaining treatment options to promote the patient's health reflects **beneficence** (doing good), while involving the patient in choosing their care respects their **autonomy** (self-determination). Why each distractor fails: - B. Paternalism involves making decisions for the patient rather than fostering shared decision-making. - C. Justice refers to equitable resource distribution and fairness, while fidelity involves keeping promises. - D. Utilitarianism focuses on allocating resources for the greatest good of the population rather than individual shared decision-making. Test-taking pearl: Combining patient education with shared decision-making bridges **beneficence** and **autonomy**. Concept tested: Clinical application of bioethical principles in patient care. Best Next Step. Best next step. Move to the next leaf under Practice Favorites covering Nonmaleficence: The duty to do no harm and minimize clinical risk to complete the foundational bioethics study sequence for board certification. Next. Topic. Sample: Rational prescribing and drug costs (Generics). Bottom Line. Bottom line. **Rational prescribing** in PMHNP practice balances clinical efficacy, safety, patient tolerability, and cost-effectiveness by selecting evidence-based, low-cost **generic** medications before expensive brand-name options. According to FDA regulatory standards, **generic** drugs must demonstrate bioequivalence within an **80% to 125%** confidence window compared to the brand-name parent drug. Prescribers must understand that while active drug molecules are chemically identical, generic preparations may contain different inactive dyes, fillers, or extended-release delivery mechanisms that can alter tolerability, cause allergic reactions, or trigger symptom relapse in sensitive patients. Key Concepts on Rational Prescribing, Generics, and Off-Label Use. * World Health Organization (**WHO**) Definition of Rational Prescribing: Patients receive medications appropriate to their clinical needs, in doses that meet their individual requirements, for an adequate period of time, at the lowest cost to them and their community. * FDA Bioequivalence Standards: * A generic drug must contain the same active ingredient, strength, dosage form, and route of administration as the brand-name product. * The FDA requires the bioequivalence parameters (area under the curve, AUC, and peak concentration, Cmax) to fall within **80% to 125%** of the parent brand-name drug. * While the average pharmacokinetic difference between brand and generic is small (approximately 3.5%), individual variations up to 20% to 25% can occur. * Switching between different generic manufacturers or from brand to generic can occasionally cause relapse (if bioavailability is lower) or toxicity/side effects (if bioavailability is higher). * Role of Inactive Ingredients: * Generic formulations often contain different inactive fillers, binders, color dyes, or sugars compared to the brand product. * Patient hypersensitivity or cutaneous rashes following a generic switch are frequently caused by inactive dyes or fillers rather than the active drug molecule itself. * Off-Label Prescribing Principles: * Defined as prescribing an FDA-approved medication for an unapproved clinical indication, an unapproved age population (e.g., pediatrics), or an unapproved dosage/duration. * Approximately **20%** of all prescriptions (and up to 50% in psychiatric practice) are written off-label. * Off-label prescribing is legal, medically accepted, and common when supported by peer-reviewed evidence, clinical guidelines, or expert consensus. * Off-label use of generic drugs in the same pharmacological class as an expensive brand-name drug is a recognized strategy to lower patient out-of-pocket costs. * There is no federal legal requirement to inform patients that a medication is off-label, but prescribers should inform patients if the use lacks literature support, carries significant risk, or is not covered by insurance. Safety Alert. Safety alert. Never assume that a sudden onset skin rash or unexpected return of psychiatric symptoms after a medication refill is an illness progression or a true drug allergy to the active molecule without checking for a recent generic switch. A new skin rash may reflect an allergic response to an inactive dye or binder in a new generic formulation, requiring a switch to a different generic manufacturer or brand rather than abandoning an effective drug class. Furthermore, when switching between generic manufacturers for narrow therapeutic index drugs or extended-release formulations (such as extended-release **bupropion** or OROS **methylphenidate**), monitor the patient closely for pharmacokinetic shifts in absorption or peak blood levels. Board Trap. Board trap. Do not select "off-label prescribing is illegal" or "written consent is legally required for all off-label uses" on board exams. Off-label prescribing is completely legal and standard in psychiatric practice. Test writers also like to test the FDA bioequivalence range (**80% to 125%**); do not be tricked into choosing "100% exact match" or "0% variance." Another trap is assuming brand-name drugs are inherently superior; first-line rational prescribing always prioritizes affordable, evidence-based **generic** medications unless a patient has a documented failure or intolerance to generic inactive components. First-Line. First-line. Your **first-line** prescribing strategy for a newly diagnosed psychiatric condition is selecting an evidence-based, low-cost **generic** medication matching the patient's symptom profile, reviewing potential drug-drug interactions, educating the patient on expected benefits and side effects, and using "start low and go slow" titration to maximize adherence and financial sustainability. Compare and Distinguish. Bioequivalence Range vs. Therapeutic Index. * Think Bioequivalence Range when: Evaluating the FDA regulatory standard (**80% to 125%**) comparing rate and extent of absorption between a generic drug and its brand-name parent compound. * Think Therapeutic Index when: Evaluating the margin of safety of a drug, measured as the ratio between the median toxic dose (**TD50**) and median effective dose (**ED50**), such as narrow therapeutic index drugs (**lithium** or **carbamazepine**). * Priority difference: Bioequivalence governs generic drug approval and manufacturing variance, whereas therapeutic index dictates laboratory blood level monitoring to prevent clinical toxicity. * What boards are testing: Differentiating manufacturing regulatory standards from drug safety profiles. Active Drug Hypersensitivity vs. Inactive Filler Allergic Reaction. * Think Active Drug Hypersensitivity when: A patient develops a true allergic reaction (e.g., IgE-mediated rash or severe cutaneous reaction) to the active pharmaceutical molecule itself, requiring complete discontinuation and avoidance of that specific drug. * Think Inactive Filler Reaction when: A patient tolerates a brand-name drug but develops a localized rash, gastrointestinal distress, or mild reaction only after switching to a generic version containing unique binders, sugars, or color dyes. * Priority difference: Active drug allergy requires switching to an unrelated chemical class, whereas inactive filler reaction can be managed by switching to a different generic manufacturer or brand name formulation. * What boards are testing: Identifying non-active pharmaceutical excipients as potential sources of adverse drug reactions. Printed Fitzgerald Sample Questions. Question 1 (Fitzgerald Sample Item). Which of the following statements regarding the off-label use of psychotropic medications is true? - A. Off-label prescribing is illegal under federal Food and Drug Administration regulations. - B. Clinicians are legally required to obtain written informed consent for all off-label prescriptions. - C. Off-label prescribing includes using an FDA-approved medication for an unapproved indication, an unapproved patient population, or as a cost-saving alternative in the same class. - D. Off-label prescribing is prohibited in pediatric and geriatric populations. Pause. Answer. C. Why it is correct: Off-label use refers to prescribing an FDA-approved drug for unapproved indications, unapproved populations (such as pediatrics or geriatrics), or as an economical generic alternative in the same class. It is a legal and widespread clinical practice. Why each distractor fails: - A. Off-label prescribing is entirely legal and recognized by major medical societies when supported by evidence or clinical judgment. - B. There is no federal legal requirement to obtain written informed consent solely because a medication is prescribed off-label, though informing patients is recommended when risks are high or literature is sparse. - C. Option C is the correct answer. - D. Off-label prescribing is extremely common in pediatric and geriatric populations due to the scarcity of FDA-approved trials in these groups. Test-taking pearl: Off-label prescribing is legal, common, and includes using generic alternatives in the same class to reduce patient costs. Concept tested: Legal and clinical principles of off-label prescribing. Question 2 (Fitzgerald Sample Item). How much different can a generic drug be from its brand name counterpart, based upon individual regulatory tests of bioequivalence? - A. 0% - B. 5% - C. 15% - D. 25% Pause. Answer. D. Why it is correct: The FDA requires that a generic medication's bioequivalence parameters (plasma AUC and Cmax) fall within **80% to 125%** of the original brand-name drug product. This allows up to a **20% to 25%** potential difference in bioequivalence testing. Why each distractor fails: - A. Choice A is incorrect because generic regulations do not require a 0% variance from brand-name products. - B. Choice B is incorrect because while the average observed bioequivalence difference in FDA studies is around 3.5% to 5%, the maximum allowed regulatory threshold is higher. - C. Choice C is incorrect because the allowable FDA bioequivalence margin extends up to 25%. - D. Option D is the correct answer. Test-taking pearl: Generic drugs must be bioequivalent to brand-name drugs within an FDA-approved range of 80% to 125%, allowing up to a 25% variance. Concept tested: FDA bioequivalence regulations for generic drugs. Live Board Practice Items. Question 3. A 32-year-old male with major depressive disorder achieves full symptomatic remission on brand-name **citalopram** 20 mg daily. Due to insurance changes, his pharmacy fills his prescription with a new generic **citalopram** formulation. Two weeks later, he develops a mild maculopapular skin rash without fever, mucosal involvement, or systemic symptoms. What is the PMHNP's most appropriate interpretation and initial action? - A. The rash is an allergy to the **citalopram** molecule; immediately stop all SSRIs permanently. - B. The rash is likely an allergic reaction to an inactive dye or binder in the generic formulation; trial a different generic manufacturer or return to brand-name **citalopram**. - C. The rash indicates acute liver failure; order an emergency liver biopsy. - D. The rash is caused by a 200% increase in drug bioequivalence; double the dose to induce tolerance. Pause. Answer. B. Why it is correct: Adverse cutaneous reactions occurring after a brand-to-generic switch are frequently caused by inactive binders, dyes, or fillers in the generic tablet rather than the active drug molecule, allowing the patient to safely try a different generic manufacturer or brand name. Why each distractor fails: - A. Since the patient previously tolerated the active **citalopram** molecule on brand-name therapy without rash, permanently banning the entire SSRI class is unnecessary and incorrect. - B. Option B is the correct answer. - C. A mild maculopapular rash without systemic symptoms does not indicate liver failure or warrant an invasive liver biopsy. - D. Doubling the dose would increase drug exposure and worsen the cutaneous hypersensitivity reaction. Test-taking pearl: Distinguish active drug allergies from inactive filler reactions when evaluating post-switch generic adverse effects. Concept tested: Clinical management of generic filler hypersensitivity. Question 4. A PMHNP is designing a treatment plan for an uninsured 42-year-old female presenting with major depressive disorder and severe financial hardship. Which prescribing strategy best exemplifies rational prescribing principles? - A. Prescribing a newly released, heavily advertised brand-name antidepressant that requires prior authorization. - B. Selecting an affordable, evidence-based generic SSRI such as **escitalopram** or **sertraline** as first-line therapy. - C. Ordering an expensive commercial pharmacogenomic saliva panel before selecting any medication. - D. Prescribing three different brand-name psychotropic medications simultaneously to accelerate response. Pause. Answer. B. Why it is correct: Rational prescribing emphasizes matching evidence-based guidelines to the patient's clinical needs using the most cost-effective, affordable **generic** options to ensure treatment adherence and financial sustainability. Why each distractor fails: - A. Choosing expensive brand-name drugs requiring complex prior authorizations creates financial barriers and non-adherence in uninsured patients. - B. Option B is the correct answer. - C. Routine commercial pharmacogenomic testing is expensive and not recommended prior to first-line trial of standard generic antidepressants. - D. Empirical polypharmacy with multiple brand-name drugs increases adverse effect risks, drug interactions, and financial burden. Test-taking pearl: Rational prescribing prioritizes evidence-based, low-cost generic options tailored to patient needs. Concept tested: Core principles of rational prescribing and cost-effective care. Best Next Step. Best next step. Move to the next leaf under Fitzgerald Sample Question Scenarios covering **Sample: Identifying principle of Beneficence** or **Scope & Standards of Practice** to complete the professional practice sequence for board certification. 💡 **Next Study Nudge:** Would you like to review **Scope & Standards of Practice** next to complete Practice Favorites, or move to **Special Populations & Practice Settings** in Chapter 2? Next. Topic. Sample: Case study on Sertraline and MDD diagnosis. Bottom Line. Bottom line. **Sertraline** is a first-line selective serotonin reuptake inhibitor (**SSRI**) frequently evaluated on board exams for treating **major depressive disorder** (**MDD**), comorbid anxiety disorders, and perinatal mood conditions. When evaluating a patient on **sertraline** presenting with new or recurrent depressive and anxious symptoms, the PMHNP must first rule out organic medical mimics (such as postpartum thyroiditis via TSH) and distinguish early transient medication side effects from true treatment failure before altering the dosage or changing medication classes. Key Concepts on Sertraline and Major Depressive Disorder Diagnosis. * Diagnostic Criteria for **Major Depressive Disorder**: Requires 5 or more out of 9 **SIGECAPS** symptoms during the same 2-week period representing a change from previous functioning, with at least one symptom being depressed mood or anhedonia (loss of interest or pleasure). * Pharmacological Profile of **Sertraline**: Selectively inhibits presynaptic serotonin reuptake; also possesses weak dopamine reuptake inhibition (DAT) and sigma-1 receptor binding, which may contribute to its mild activating properties. * Perinatal and Lactation Safety: **Sertraline** is one of the most extensively studied SSRIs in pregnancy and breastfeeding due to its low relative infant dose (RID) and minimal passage into breast milk, making it a preferred first-line choice for postpartum **MDD**. * Early Side Effect Timeline: Frontal headaches, mild gastrointestinal upset, and transient nervousness often occur during the first 1 to 2 weeks of **sertraline** initiation and typically resolve spontaneously with continued dosing. * Medical Mimics in Depressive Presentations: Endocrine disorders, specifically **hypothyroidism** or postpartum thyroiditis, frequently present with fatigue, weight changes, mood lability, and sleep disruption, mimicking **MDD** relapse. Safety Alert. Safety alert. Never escalate an antidepressant dose or label a trial as a treatment failure when a patient experiences early mild side effects, such as a frontal headache or mild nausea, after only 1 week on **sertraline**. Additionally, when a postpartum woman on stable **sertraline** develops new anxiety and fatigue, do not automatically double the antidepressant dose without first checking a TSH to rule out postpartum thyroiditis. Initiating or increasing psychotropics without ruling out endocrine pathology delays essential medical care and exposes the patient to unnecessary medication toxicity. Board Trap. Board trap. Do not assume that a return of depressive or anxious symptoms in a postpartum woman on stable **sertraline** represents a primary psychiatric relapse or medication tolerance. Test writers use postpartum vignettes to tempt candidates into choosing "increase **sertraline**" or "refer to psychotherapy." The correct board response is obtaining a TSH level to evaluate for postpartum thyroid dysfunction. Another trap is mistaking early 1-week SSRI side effects (like transient headache) for treatment failure or drug allergy; educate the patient and maintain the trial. First-Line. First-line. Your **first-line** action when evaluating a patient with **major depressive disorder** who reports new or changing symptoms while on **sertraline** is conducting a thorough medical rule-out (including TSH and baseline labs), assessing medication adherence and therapeutic trial duration (4 to 8 weeks at a therapeutic dose), and utilizing standardized rating scales like the PHQ-9 to quantify clinical response. Compare and Distinguish. Postpartum Major Depression vs. Postpartum Thyroiditis. * Think Postpartum Major Depression when: Sustained depressed mood, severe anhedonia, worthlessness, and crying spells persist past 2 weeks postpartum without physical signs of thyroid enlargement or laboratory abnormalities. * Think Postpartum Thyroiditis when: Transient hyperthyroid symptoms (anxiety, palpitations, insomnia) followed by hypothyroid symptoms (profound fatigue, dry skin, constipation, weight gain) develop 2 to 6 months after delivery in a previously stable patient. * Priority difference: Postpartum depression requires evidence-based psychotherapy and lactation-aware antidepressants like **sertraline**, whereas postpartum thyroiditis requires TSH and free T4 laboratory evaluation and medical endocrine management. * What boards are testing: Prioritizing endocrine medical rule-outs before adjusting psychiatric medications. Early SSRI Side Effects vs. Antidepressant Treatment Failure. * Think Early SSRI Side Effects when: Mild frontal headaches, nausea, loose stools, or transient jitteriness occur within 1 to 2 weeks of starting **sertraline** in a patient whose depression has not yet had time to respond. * Think Antidepressant Treatment Failure when: Depressive symptoms show zero improvement after 6 to 8 weeks of adherent dosing at a maximum tolerated therapeutic dose. * Priority difference: Early side effects require reassurance, symptomatic support, and continuing the trial, whereas true treatment failure warrants dose optimization, switching, or augmentation. * What boards are testing: Understanding pharmacodynamic onset timelines and avoiding premature medication changes. Printed Fitzgerald Sample Questions. Question 1 (Fitzgerald Sample Item). You follow Mrs. Thomas for anxiety and depression, which have been stable for many years on sertraline 50 mg daily. Today she is 2 months postpartum following an uncomplicated delivery. She relates difficulty with sleep, irritability, fatigue, and a return of anxiety. She states, "I am doing fine with breastfeeding, and he is a good baby." What is the PMHNP's most appropriate response? - A. "I am certain that these symptoms are just normal adjustments to delivery." - B. "I would like to get a TSH to check your thyroid function." - C. "We should double your sertraline dose to 100 mg daily immediately." - D. "We need to discontinue sertraline and initiate bupropion." Pause. Answer. B. Why it is correct: Postpartum thyroiditis frequently presents 2 to 6 months after delivery with fatigue, sleep disruption, anxiety, and irritability that closely mimic a psychiatric relapse. Obtaining a TSH level rules out an underlying endocrine disorder before modifying psychiatric medication. Why each distractor fails: - A. Dismissing new symptoms as normal postpartum adjustment ignores potential medical and psychiatric pathologies. - B. Option B is the correct answer. - C. Doubling the **sertraline** dose without ruling out medical causes like thyroiditis is premature and risks medication toxicity. - D. Discontinuing **sertraline** and starting **bupropion** is inappropriate, especially in a breastfeeding patient where **sertraline** has a superior lactation safety profile and thyroid disease has not been ruled out. Test-taking pearl: Always check thyroid function (TSH) when a previously stable patient develops new mood or anxiety symptoms postpartum. Concept tested: Endocrine medical rule-outs in postpartum psychiatric presentations. Question 2 (Fitzgerald Sample Item). You see a 45-year-old woman with major depressive disorder who started taking standard-dose sertraline 1 week ago. She returns today with a chief complaint of "not really feeling any better. In fact, I think I might feel worse. I have this on and off headache right over my eyes since I started the medication." Physical examination is unremarkable, with intact cranial nerves and clear speech. Which of the following is the most appropriate advice to provide? - A. Discontinue sertraline immediately because headache indicates an allergic reaction. - B. Switch to fluoxetine because sertraline has failed to produce a response. - C. Increase the sertraline dose immediately to achieve therapeutic blood levels. - D. Reassure the patient that frontal headache is a common short-term side effect that usually resolves, and continue the medication trial. Pause. Answer. D. Why it is correct: Mild frontal headaches and transient symptom amplification are recognized early, temporary side effects of **sertraline** that typically diminish within 1 to 2 weeks. Antidepressants require 4 to 8 weeks for therapeutic response, so continuing the trial with reassurance is the correct action. Why each distractor fails: - A. A mild frontal headache is a common serotonergic side effect, not a sign of a true drug allergy or dangerous toxicity. - B. Switching medications after only 1 week is premature because therapeutic efficacy cannot be evaluated in such a short window. - C. Increasing the dose immediately would worsen serotonergic side effects like headache without speeding up therapeutic onset. - D. Option D is the correct answer. Test-taking pearl: Allow 4 to 8 weeks for antidepressant response and manage early transient side effects with reassurance before declaring treatment failure. Concept tested: Management of early SSRI side effects and trial duration. Question 3 (Fitzgerald Sample Item). A 36-year-old married physician who is seen monthly for cluster B personality traits presents with a 1-month history of pervasive depressed mood, anhedonia, insomnia, and fatigue consistent with major depressive disorder. Which of the following is the most appropriate first-line psychotropic agent? - A. Olanzapine - B. Lithium - C. Sertraline - D. Amitriptyline Pause. Answer. C. Why it is correct: When a patient with a personality disorder experiences a distinct co-occurring major depressive episode, the PMHNP should treat the **MDD** with a standard first-line antidepressant, such as the SSRI **sertraline**. Why each distractor fails: - A. **Olanzapine** is an atypical antipsychotic indicated for schizophrenia or bipolar mania, not first-line unipolar non-psychotic **MDD**. - B. **Lithium** is a mood stabilizer used for bipolar disorder and suicide risk reduction, not first-line for unipolar **MDD**. - C. Option C is the correct answer. - D. **Amitriptyline** is a tricyclic antidepressant with high anticholinergic, sedating, and cardiac toxicity risks, making it second- or third-line. Test-taking pearl: Treat co-occurring major depressive episodes in patients with personality traits using standard first-line SSRIs. Concept tested: First-line pharmacotherapy for MDD co-occurring with personality traits. Live Board Practice Items. Question 4. A 22-year-old male with type 1 diabetes mellitus and generalized anxiety disorder has been successfully treated for recurrent major depressive disorder with sertraline 100 mg daily. He has been completely symptom-free for 6 months and asks to stop his medication. What is the PMHNP's most appropriate clinical rationale when counseling him to maintain antidepressant therapy? - A. His young age automatically mandates lifelong psychotropic treatment regardless of episode count. - B. His history of recurrent major depressive episodes places him at a significantly higher risk for depressive relapse if medication is discontinued. - C. Stopping sertraline will cause immediate irreversible renal failure due to his type 1 diabetes. - D. Sertraline cannot be discontinued once initiated because it permanently alters serotonin receptors. Pause. Answer. B. Why it is correct: Guidelines recommend maintenance antidepressant therapy (often 1 to 2 years or longer) for patients with recurrent **MDD** (two or more episodes) because their risk of relapse upon discontinuation exceeds 50% to 80%. Why each distractor fails: - A. Age alone does not mandate lifelong therapy; episode recurrence and severity dictate maintenance length. - B. Option B is the correct answer. - C. **Sertraline** does not cause acute renal failure, and diabetes management does not contraindicate maintenance SSRI therapy. - D. SSRIs can be safely tapered and discontinued when clinically appropriate; they do not cause permanent receptor damage. Test-taking pearl: Recurrent MDD (2 or more episodes) is a primary indication for continuation or maintenance antidepressant therapy to prevent relapse. Concept tested: Indications for maintenance pharmacotherapy in recurrent major depressive disorder. Best Next Step. Best next step. Move to the next leaf under Fitzgerald Sample Question Scenarios covering **Scope & Standards of Practice: Advanced practice psychiatric nursing roles, consultation, and collaborative care models** to master national practice boundaries, interprofessional care delivery, and leadership regulations for board certification. 💡 **Next Study Nudge:** Would you like to cover **Scope & Standards of Practice** next to complete Practice Favorites, or move on to **Special Populations & Practice Settings** in Fitzgerald Chapter 2? Next. End of this drive.